FCA
ICPT

FinTrust Capital Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

FinTrust Capital Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,207
Closed -$22.4K – 1363
2023
Q3 		$22.4K Sell
1,207
-419
-26% -$4.74K 0.01% 640
2023
Q2 		$20.1K Hold
1,626
– – ﹤0.01% 653
2023
Q1 		$20.1K Hold
1,626
– – ﹤0.01% 650
2022
Q4 		$20.1K Buy
1,626
+347
+27% +$4.91K ﹤0.01% 648
2022
Q3 		$17K Sell
1,279
-409
-24% -$6.59K ﹤0.01% 761
2022
Q2 		$24K Buy
1,688
+276
+20% +$4.42K 0.01% 697
2022
Q1 		$23K Buy
1,412
+354
+33% +$5.54K 0.01% 742
2021
Q4 		$17K Buy
+1,058
New +$17.8K ﹤0.01% 794

FinTrust Capital Advisors's ICPT Position: Q4 2023 in Review

FinTrust Capital Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 1,207 shares — an estimated $22.4K sold.

FinTrust Capital Advisors first reported a position in ICPT in Q4 2021 and held it in 8 quarters. The position peaked at $24K in Q2 2022. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • FinTrust Capital Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • FinTrust Capital Advisors sold 1,207 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $22.4K.
  • FinTrust Capital Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 8 quarters.
  • FinTrust Capital Advisors's Intercept Pharmaceuticals, Inc. position peaked at $24K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on FinTrust Capital Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.